Atea Pharmaceuticals (AVIR) FCF Margin (2021)
Atea Pharmaceuticals (AVIR) posted quarterly FCF Margin of 39.25% for Q4 2021, down 156.97% quarter-over-quarter from 68.89% in Q3 2021.
Powered by 
Analysis
Atea Pharmaceuticals (AVIR) FCF Margin (2021) Analysis & Trends
Atea Pharmaceuticals' FCF Margin history runs 1 years deep, the most recent figure standing at 39.25% for Q4 2021.
- In Q4 2021, FCF Margin changed N/A year-over-year to 39.25%; the TTM figure through Dec 2021 stood at 24.76% (changed N/A YoY), while the FY2021 annual figure was 24.76%, down 63486.0% from the prior year.
- FCF Margin for Q4 2021 stood at 39.25%, down from 68.89% in the prior quarter.
- The five-year high for FCF Margin was 68.89% in Q3 2021, with the low at 39.25% in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 70.82% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 10 | Atea Pharmaceuticals | 469.10 Mn | 469.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | -39.25% |
| Sep 30, 2021 | 68.89% |
| Jun 30, 2021 | -28.73% |
| Mar 31, 2021 | -25.52% |